

# Carmen Tur

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8066586/carmen-tur-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91  
papers

3,263  
citations

28  
h-index

56  
g-index

109  
ext. papers

4,120  
ext. citations

5.8  
avg. IF

5.02  
L-index

#	Paper	IF	Citations
91	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 597-606	15	321
90	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. <i>Brain</i> , <b>2015</b> , 138, 1863-74	11.2	302
89	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 471-82	15	272
88	Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. <i>Neurology</i> , <b>2008</b> , 70, 1079-83	6.5	265
87	Deep gray matter volume loss drives disability worsening in multiple sclerosis. <i>Annals of Neurology</i> , <b>2018</b> , 83, 210-222	9.4	185
86	Neurite dispersion: a new marker of multiple sclerosis spinal cord pathology?. <i>Annals of Clinical and Translational Neurology</i> , <b>2017</b> , 4, 663-679	5.3	148
85	Progression of regional grey matter atrophy in multiple sclerosis. <i>Brain</i> , <b>2018</b> , 141, 1665-1677	11.2	146
84	Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 479-84	5	97
83	Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. <i>JAMA Neurology</i> , <b>2017</b> , 74, 970-976	17.2	94
82	Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. <i>Nature Reviews Neurology</i> , <b>2018</b> , 14, 75-93	15	84
81	Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1175-81	5	75
80	Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. <i>Brain</i> , <b>2015</b> , 138, 2584-95	11.2	71
79	Neurofilament light chain level is a weak risk factor for the development of MS. <i>Neurology</i> , <b>2016</b> , 87, 1076-84	6.5	61
78	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 301-312	5	55
77	Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD. <i>Neurology</i> , <b>2018</b> , 90, e1183-e1190	6.5	50
76	Fatigue Management in Multiple Sclerosis. <i>Current Treatment Options in Neurology</i> , <b>2016</b> , 18, 26	4.4	50
75	Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis. <i>Brain</i> , <b>2016</b> , 139, 816-28	11.2	46

74	Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 322-330	5	45
73	Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 55-61	5	45
72	Fully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg: Application to multiple sclerosis. <i>NeuroImage: Clinical</i> , <b>2016</b> , 10, 71-7	5.3	44
71	Brain atrophy in natalizumab-treated patients: A 3-year follow-up. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 749-56	5	43
70	Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. <i>European Journal of Neurology</i> , <b>2012</b> , 19, 899-904	6	42
69	Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis. <i>European Radiology</i> , <b>2018</b> , 28, 3779-3788	8	41
68	Significant clinical worsening after natalizumab withdrawal: Predictive factors. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 780-5	5	37
67	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. <i>Neurology</i> , <b>2016</b> , 87, 1368-74	6.5	37
66	Interferon β1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. <i>Archives of Neurology</i> , <b>2011</b> , 68, 1421-7		34
65	Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 1602-8	5	33
64	Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 932-941	5	31
63	Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. <i>Multiple Sclerosis Journal</i> , <b>2009</b> , 15, 1459-65	5	26
62	Structural network disruption markers explain disability in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 219-226	5.5	24
61	Grey matter damage and overall cognitive impairment in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2011</b> , 17, 1324-32	5	22
60	Natalizumab: risk stratification of individual patients with multiple sclerosis. <i>CNS Drugs</i> , <b>2014</b> , 28, 641-8	6.7	21
59	Risk acceptance in multiple sclerosis patients on natalizumab treatment. <i>PLoS ONE</i> , <b>2013</b> , 8, e82796	3.7	21
58	Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis. <i>Neurology</i> , <b>2018</b> , 91, e1130-e1134	6.5	20
57	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 1193-6	5	19

56	Complementary roles of grey matter MTR and T2 lesions in predicting progression in early PPMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2011</b> , 82, 423-8	5.5	18
55	Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS. <i>Journal of Neurology</i> , <b>2010</b> , 257, 742-6	5.5	18
54	Relevance of time-dependence for clinically viable diffusion imaging of the spinal cord. <i>Magnetic Resonance in Medicine</i> , <b>2019</b> , 81, 1247-1264	4.4	18
53	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1658-1669	5	18
52	Mind the gap: from neurons to networks to outcomes in multiple sclerosis. <i>Nature Reviews Neurology</i> , <b>2021</b> , 17, 173-184	15	18
51	Grey matter atrophy is associated with disability increase in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 556-566	5	17
50	Value of NMO-IgG determination at the time of presentation as CIS. <i>Neurology</i> , <b>2012</b> , 78, 1608-11	6.5	15
49	Very early scans for demonstrating dissemination in time in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 631-5	5	15
48	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 1352458520925369	5	14
47	HLA-DRB1*15 influences the development of brain tissue damage in early PPMS. <i>Neurology</i> , <b>2014</b> , 83, 1712-8	6.5	14
46	Head-to-head drug comparisons in multiple sclerosis: Urgent action needed. <i>Neurology</i> , <b>2019</b> , 93, 793-809	5	13
45	Progressive MS trials: Lessons learned. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1583-1592	5	12
44	In vivo imaging of chronic active lesions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 1352458520958589	5	12
43	Structural cortical network reorganization associated with early conversion to multiple sclerosis. <i>Scientific Reports</i> , <b>2018</b> , 8, 10715	4.9	10
42	Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSI. <i>Human Brain Mapping</i> , <b>2014</b> , 35, 993-1003	5.9	9
41	Clinical relevance of cortical network dynamics in early primary progressive MS. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 442-456	5	9
40	High-dimensional detection of imaging response to treatment in multiple sclerosis. <i>Npj Digital Medicine</i> , <b>2019</b> , 2, 49	15.7	8
39	A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 774-785	5	8

38	Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 28-38	5	8
37	Brain microstructural and metabolic alterations detected in vivo at onset of the first demyelinating event. <i>Brain</i> , <b>2021</b> , 144, 1409-1421	11.2	7
36	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 1352458520924595	5	6
35	HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 7, 47-52	4	6
34	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. <i>Neurology</i> , <b>2021</b> , 97, e1641-e1652	6.5	6
33	An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. <i>Revista De Neurologia</i> , <b>2011</b> , 52, 321-30	24	6
32	CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: No. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 717-8	5	5
31	Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	5
30	Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 721-727	5	3
29	Multiple sclerosis risk perception and acceptance for Brazilian patients. <i>Arquivos De Neuro-Psiquiatria</i> , <b>2018</b> , 76, 6-12	1.6	3
28	Secondary progression is not the only explanation. <i>Acta Medica Portuguesa</i> , <b>2014</b> , 27, 393-6	1.4	3
27	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	3
26	Single-subject structural cortical networks in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1392-1401	5	3
25	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	3
24	Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.. <i>Neurology</i> , <b>2022</b> ,	6.5	3
23	Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis. <i>NeuroImage: Clinical</i> , <b>2022</b> , 35, 103048	5.3	3
22	Disrupted principal network organisation in multiple sclerosis relates to disability. <i>Scientific Reports</i> , <b>2020</b> , 10, 3620	4.9	2
21	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1802-10	5	2

20	NMO spectrum disorders: how wide is the spectrum?. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 1417-9	5	2
19	Subcutaneous alemtuzumab for multiple sclerosis. <i>Expert Review of Clinical Immunology</i> , <b>2012</b> , 8, 423-6	5.1	2
18	Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique. <i>NeuroImage: Clinical</i> , <b>2021</b> , 33, 102904	5.3	2
17	Sodium in the Relapsing-Remitting Multiple Sclerosis Spinal Cord: Increased Concentrations and Associations With Microstructural Tissue Anisotropy. <i>Journal of Magnetic Resonance Imaging</i> , <b>2020</b> , 52, 1429-1438	5.6	2
16	Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2021</b> ,	5.5	2
15	Commentary on Pique et al.'s paper entitled: Peripheral late reactivation of a previously typical monofocal Balo's concentric sclerosis lesion. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1084-6	5	1
14	Secondary progressive NMO, or concomitant NMO and a primary neurodegenerative disorder?. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1876-8	5	1
13	Progression of regional grey matter atrophy in multiple sclerosis		1
12	Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2021</b> , 92, 995-1006	5.5	1
11	Machine and deep learning in MS research are just powerful statistics - Yes. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 661-662	5	1
10	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. <i>Multiple Sclerosis Journal</i> , <b>2022</b> , 13524585211069068	5	1
9	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , <b>2022</b> , 13524585221089540	5	1
8	Translating pH-sensitive PROgressive saturation for QUantifying Exchange rates using Saturation Times (PRO-QUEST) MRI to a 3T clinical scanner. <i>Magnetic Resonance in Medicine</i> , <b>2020</b> , 84, 1734-1746	4.4	0
7	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.. <i>Journal of Neurology</i> , <b>2022</b> , 269, 1764	5.5	0
6	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211053001	5	0
5	Assessing Lumbar Plexus and Sciatic Nerve Damage in Relapsing-Remitting Multiple Sclerosis Using Magnetisation Transfer Ratio.. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 763143	4.1	0
4	Spatial Characterisation of Fibre Response Functions for Spherical Deconvolution in Multiple Sclerosis. <i>Mathematics and Visualization</i> , <b>2019</b> , 265-279	0.6	
3	Comment on severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 660-1	5	

- |   |   |     |
|---|---|-----|
| 2 | Comment on Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option? S Maillart et al. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 510-1 | 5   |
| 1 | An overview of the association between gray matter damage and cognitive impairment in multiple sclerosis. <i>Neurodegenerative Disease Management</i> , <b>2012</b> , 2, 503-515                                | 2.8 |